Interceptor Plus is a drug owned by ELANCO US INC. It is protected by 2 US drug patents filed from 2024 to 2028. Out of these, 1 patent is active and 1 patent has expired. Details of Interceptor Plus’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US8541019 | 29 Jul, 2024 | Expired |
Exclusivity Information
Interceptor Plus holds 1 exclusivity out of which 1 has expired. Details of Interceptor Plus's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Jun 21, 2020 |
About Interceptor Plus
Interceptor Plus is a drug
owned by ELANCO US INC.
Interceptor Plus uses
Milbemycin Oxime, Praziquantel as the active
ingredients.
Active Ingredient:
Interceptor Plus uses
Milbemycin Oxime,
Praziquantel
as the active ingredients.
Check out other Drugs and Companies using
Milbemycin Oxime, Praziquantel ingredient.